What Is Lunsumio Velo, and Why Does It Matter? Lunsumio Velo (mosunetuzumab-axgb) is a new under-the-skin (subcutaneous) injection version of the anticancer medicine Lunsumio intravenous infusion. The ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up PURPOSE: Unlike nodal follicular lymphoma (NFL), Primary cutaneous follicular lymphomas (PCFLs) rarely express Bcl-2 ...

Studies demonstrating high response rates and manageable safety profiles, along with FDA approvals, have supported bispecific antibodies as promising treatment options for follicular lymphoma. At the ...

The shift toward dual-targeting bispecifics and the imminent arrival of highly efficacious triple combinations could shift the follicular lymphoma treatment space. The future treatment landscape for ...

"Random skin biopsies are utilized when there is a sufficiently high concern of the diagnosis in the patient and they do not have overt clinical findings suggestive of the diagnosis. In those cases, ...

Lunsumio VELO, a subcutaneous CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two systemic therapies. The GO29781 study reported a 75% objective response ...

Follicular Lymphoma: Symptoms, Causes, Diagnosis and Treatment: By Shreoshree Chakrabarty Follicular Lymphoma is a common type of non-Hodgkin lymphoma that develops in the lymphatic system, affecting ...

Explore the advancements in bispecific antibodies for follicular lymphoma, addressing treatment options, toxicities, and unmet patient needs in cancer care. Bispecific antibodies were developed to ...

BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today ...